Clinical trials: Asthma Patients
Asthma
Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma
Efficacy and tolerability of the fixed combination Beclomethasone Dipropionate /Formoterol in patients with mild to moderate persistent asthma.
- Trial name
- NCT00862264
- Testing
- Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
- Volunteers
- 286 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma Bronchiale, Bronchiectasis
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with airway mucus hypersecretion in chronic airway inflammatory diseases
- Conditions
- Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06820749
- Testing
- HSK31858
- Where
- China
- Volunteers
- 309 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma
This study is a randomized, double-Blind, placebo-controlled, Single and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in…
- Trial name
- NCT07436949
- Testing
- BBT002
- Where
- 12 sites in China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics
Allergic Rhinitis, Rhinoconjunctivitis
Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma
Safety study of Depigoid vaccine Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), to treat allergic rhinitis or rhinoconjunctivitis with or without asthma.
- Conditions
- Allergic Rhinitis, Rhinoconjunctivitis, Mild Persistent Asthma, Mild Intermittent Asthma
- Trial name
- NCT01591343
- Testing
- Depigoid® (500 DPP/ml)
- Where
- 10 sites in Spain
- Volunteers
- 8 people
- Sponsor
- Laboratorios Leti, S.L.
Chronic Rhinosinusitis With Nasal Polyps, Asthma
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives To evaluate the efficacy of dupilumab in improving chronic…
- Trial name
- EVEREST (NCT04998604)
- Testing
- Dupilumab, Omalizumab
- Where
- 87 sites in United States, Belgium and 15 more
- Volunteers
- 360 people
- Sponsor
- Sanofi
Asthma
Efficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence
The goal of this observational study is to determine if using the SiA® (Systematic Intervention Agent) system can improve inhaler technique and medication adherence in adults with asthma who are already using Trimbow pMDI…
- Trial name
- SiASMARTer (NCT06908421)
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Chiesi Pharma AB, Nordic
Asthma
Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid
To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.
- Trial name
- NCT00174733
- Testing
- Ciclesonide (XRP1526)
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- Sanofi
Asthma
A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449
This will be a Phase I, first in human (FIH) study consisting of the following parts: Part 1a (SAD), Part 1b (IV Cohort), Part 2 (Multiple ascending dose (MAD), and Part 3 dry-powder inhalation (DPI)/ Proof of mechanism (PoM).
- Trial name
- NCT03766399
- Testing
- AZD0449
- Where
- 4 sites in Germany, New Zealand and 1 more
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma
The primary objective of this study is to compare the pharmacokinetic (PK) profiles of Albuterol Spiromax® and ProAir HFA after administration of a single inhaled dose of 180 mcg albuterol base from each product.
- Trial name
- NCT01844401
- Testing
- Albuterol Spiromax®, ProAir® HFA
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Study of RO5036505 in Patients With Moderate to Severe Asthma
This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of RO5036505 in patients with inadequately controlled moderate to severe asthma.
- Trial name
- NCT00967590
- Testing
- RO5036505
- Where
- 16 sites in United States, United Kingdom
- Sponsor
- Hoffmann-La Roche
Asthma
Integrated Digitally Enhanced Care for Long-term Conditions- Asthma
Asthma is a common lung condition that causes long term breathing difficulties. There is currently no cure for asthma but the use of simple inhaler treatments can keep the symptoms under control.
- Trial name
- IDEAL (NCT03511482)
- Testing
- myAsthma Application, Lloyds Pharmacy Online Doctor
- Where
- United Kingdom
- Sponsor
- my mhealth Ltd
Asthma
A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma
The primary objective will be to compare the formulations regarding their impact on the pulmonary function of persistent asthma patients and the secondary objective will be the clinical control of the disease's symptoms.
- Trial name
- CAINAS SF (NCT01202097)
- Testing
- Salmeterol/Fluticasone, Seretide
- Where
- 6 sites in Brazil
- Volunteers
- 334 people
- Sponsor
- Eurofarma Laboratorios S.A.
Persistent Asthma
A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
This is a randomized, double-blind, placebo-controlled parallel-group study. Participants will be randomly assigned to receive treatment with beclomethasone dipropionate at a dosage of 80 or 160 mcg/day delivered via a…
- Trial name
- NCT02040779
- Testing
- Beclomethasone dipropionate breath-actuated inhaler, albuterol/salbutamol
- Where
- 47 sites in United States
- Volunteers
- 273 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201
This study planned to assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.
- Trial name
- NCT02075008
- Testing
- QGE031
- Where
- 84 sites in United States, Argentina and 18 more
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma
This study investigated asthma-related quality of life in Brazilian patients using omalizumab.
- Trial name
- NCT00567476
- Testing
- Omalizumab, Inhaled corticosteroids (ICS), Long-acting beta 2-adrenergic agonist (LABA)
- Where
- Brazil
- Volunteers
- 116 people
- Sponsor
- Novartis
Allergic Rhinitis Due to Cat Allergy
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
The primary objective of the study is to determine the efficacy of REGN1908-1909, as compared to placebo, to reduce allergic rhinitis/conjunctivitis symptoms and allergy rescue medication use during natural cat exposure.
- Trial name
- NCT04981717
- Testing
- REGN1908-1909
- Where
- 92 sites in United States, Belgium and 4 more
- Volunteers
- 446 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of lebrikizumab in patients with asthma whose disease remains uncontrolled despite daily therapy with an…
- Trial name
- NCT01545440
- Testing
- lebrikizumab
- Where
- 71 sites in United States, Australia
- Volunteers
- 258 people
- Sponsor
- Genentech, Inc.
Asthma
A Study Of GSK679586A When Infused Into Healthy And Mild Asthmatic Volunteers
This is a two part study. Part I is designed to test single doses of GSK678586A in healthy volunteers. Part II is designed to test repeat doses (two doses) of GSK679586A in patients with mild asthma.
- Trial name
- NCT00411814
- Testing
- GSK679586
- Where
- 2 sites in Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Allergy to House Dust Mite, Allergic Asthma
Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients
The study will be conducted as a randomized, double-blind, placebo-controlled, single-center study in adult patients with mild controlled allergic asthma and house dust mite allergy.
- Trial name
- Tregulaire (NCT04673591)
- Testing
- Tregalizumab
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- T-Balance Therapeutics GmbH
Asthma
A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy
This study has the objective of providing compassionate use access to omalizumab (Xolair) and to evaluate the Safety of Xolair in subjects with severe allergic asthma who remain symptomatic despite optimal therapy according to…
- Trial name
- NCT00639691
- Testing
- omalizumab
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Novartis